Felip E, Wakelee HA, Fu C, Deng Y, et al. Reply to: "Improving the Reporting of Long-Term Effects in the IMpower010 Trial" and "Adjuvant Atezolizumab in Early-Stage Non-Small Cell Lung Cancer: Signals, Silences, and the Need for Methodological Clarity". J Clin Oncol 2025 Dec 10:JCO2502102. doi: 10.1200/JCO-25-02102.
PMID: 41370740